Generic Pharmaceuticals Contract Manufacturing Market Expected To Reach $93.56 Billion By 2030 As Growth Accelerates At 6.9% CAGR
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Generic Pharmaceuticals Contract Manufacturing Market CAGR Analysis And Future Market Development
The market for contract manufacturing in the generic pharmaceutical sector has experienced robust expansion in recent years. Projections indicate a rise from $66.82 billion in 2025 to $71.65 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.2%. Key factors driving this historical growth include a scarcity of contract manufacturing alternatives, heavy dependence on in-house production of generic drugs, heightened demand for off-patent active pharmaceutical ingredients (APIs), an uptick in generic medication approvals, and ongoing cost constraints faced by pharmaceutical firms.
The generic pharmaceuticals contract manufacturing market is forecasted to experience considerable expansion in the coming years. By 2030, it is projected to reach $93.56 billion, representing a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period is driven by factors such as the rising global demand for generic drugs, the expansion of contract manufacturing organizations (CMOs), the adoption of advanced formulation technologies, a growing emphasis on biologics and complex generics, and increased cross-border regulatory collaborations. Key trends shaping this period include the growing trend of outsourcing generic drug production, a focus on cost-efficient manufacturing and packaging methods, the broadening of injectable and tablet manufacturing services, enhanced regulatory support and compliance offerings, and the expansion of licensing and technology transfer activities for generic products.
Download A Free Sample Report For Comprehensive Market Insights:
Generic Pharmaceuticals Contract Manufacturing Market Development Factors: Which Trends Are Supporting Demand?
The growth of the generic pharmaceuticals contract manufacturing market is anticipated to be driven by the increasing demand for biosimilars. These biologic medical products closely resemble previously authorized reference biologics, showing no clinically significant variations in safety, purity, or effectiveness. This rising interest is largely attributed to their ability to offer affordable substitutes for expensive biologic drugs, thereby improving access to advanced therapies for patients and healthcare systems alike. Through cost-efficient large-scale manufacturing and regulatory knowledge, generic pharmaceutical contract manufacturing accelerates biosimilar market entry while upholding consistent quality standards. As an example, Cardinal Health Inc., a U.S.-based healthcare firm, reported in January 2023 that by January 2022, 33 biosimilar products had been approved by the FDA in the U.S., with 21 commercially available; by 2023, FDA-approved biosimilars climbed to 40, with 25 reaching the market. Consequently, the escalating demand for biosimilars is fueling expansion in the generic pharmaceuticals contract manufacturing sector.
Generic Pharmaceuticals Contract Manufacturing Market Segment Breakdown: Which Categories Generate The Most Revenue?
The generic pharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Drug Type: Branded Generics, Unbranded Generics
2) By Product Type: Pharmaceutical Active Pharmaceutical Ingredients, Formulations, Capsules, Tablets, Injectables
3) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
4) By Application: Oncology, Immunology, Antidiabetic, Neurology, Anticoagulants, Cardiovascular, Respiratory, Pain, Human Immunodeficiency Virus Antivirals
5) By End-User Industry: Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Generic Drug Manufacturers
Subsegments:
1) By Branded Generics: Contract Development of Branded Formulations, Branded Generic Tablet Manufacturing, Branded Injectable Manufacturing, Packaging and Labeling for Branded Generics, Regulatory Support For Branded Generics
2) By Unbranded Generics: Bulk Manufacturing of Off-Patent Active Pharmaceutical Ingredients, Generic Tablet Or Capsule Production, Parenteral Or Injectable Generic Manufacturing, Cost-Efficient Packaging for Unbranded Products, Licensing And Tech Transfer for Generic Products
Generic Pharmaceuticals Contract Manufacturing Market Transformation Trends: Which Innovations Are Driving Change?
To address the rising demand for outsourced development and manufacturing, major players in the generic pharmaceutical contract manufacturing market are enhancing their service offerings through the creation of specialized subsidiaries. By establishing these dedicated units, companies can streamline active pharmaceutical ingredient (API) production while ensuring compliance, scalability, and operational effectiveness across the entire drug development process. A notable example occurred in July 2025, when Lupin, an Indian generic pharmaceutical firm, launched Lupin Manufacturing Solutions (LMS) as a new subsidiary to enter the contract development and manufacturing organization (CDMO) space. This focused division is designed to support the development, production, and sale of APIs for global pharmaceutical partners. Backed by a leadership team with extensive experience in biotech and pharma, the subsidiary is well-equipped to deliver high-quality contract services, enabling pharmaceutical companies to reduce time-to-market while upholding regulatory standards and cost efficiency.
Generic Pharmaceuticals Contract Manufacturing Market Key Players And Strategic Industry Positioning
Major companies operating in the generic pharmaceuticals contract manufacturing market are WuXi AppTec Co. Ltd., Recipharm AB, Siegfried Holding AG, Curia Global Inc., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Alcami Corp. Inc, Neuland Laboratories Limited.
Access The Complete Generic Pharmaceuticals Contract Manufacturing Market Report:
Generic Pharmaceuticals Contract Manufacturing Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
